Evidence map›Paper›PMID 34967364›Full record

ArticleMedicine2021

Susceptibility of ABO blood group to COVID-19 infections: clinico-hematological, radiological, and complications analysis.

Saeed M Kabrah, Samer S Abuzerr, Mohammed A Baghdadi, Ahmed M Kabrah, Arwa F Flemban, Fayez S Bahwerth, Hamza M Assaggaf, Eisa A Alanazi, Abdullah A Alhifany, Sarah A Al-Shareef and 9 more

Abstract read
In one paragraph

Article in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Differential expression ofJournal of Taibah University Medical Sciences · 2024
    Article
  6. Article
  7. Article
  8. Observational
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Saeed M KabrahLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.ORCID 0000-0003-2992-8497
Samer S AbuzerrVisiting Scholar with the School of Public Health, Department of Social and Preventive Medicine, University of Montreal, Montreal, Canada.
Mohammed A BaghdadiResearch Centre, King Faisal Specialist Hospital and Research Centre Jeddah, Kingdom of Saudi Arabia.
Ahmed M KabrahLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Arwa F FlembanPathology Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Fayez S BahwerthLaboratory and Blood Bank Department, King Faisal Hospital, Makkah, Kingdom of Saudi Arabia.
Hamza M AssaggafLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Eisa A AlanaziComputer Science Department, Faculty of Computer and Information System, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Abdullah A AlhifanyClinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Sarah A Al-ShareefComputer Science Department, Faculty of Computer and Information System, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Wesam H AlsabbanInformation System Department, Faculty of Computer and Information Systems, Umm Al Qura University, Makkah, Kingdom of Saudi Arabia.
Anmar A KhanLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Hissah AlzhraniMathematical Sciences Department, Faculty of Applied Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Layal K JambiRadiological Sciences Department, College of Applied Medical Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Radi T AlsafiLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Akhmed AslamLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Hebah M KabrahLaboratory and Blood Bank Department, Al Noor Specialist Hospital, Makkah, Kingdom of Saudi Arabia.
Ahmad O BabalghithMedical Genetic Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Amr J HalawaniLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.

Funding

Institute of Manuscripts and Revival of Islamic Heritage, Umm Al-Qura University 20-MED-4-13-0013
6 · The paper itself

Abstract

abstractIn the wake of the COVID-19 pandemic, research indicates that the COVID-19 disease susceptibility varies among individuals depending on their ABO blood groups. Researchers globally commenced investigating potential methods to stratify cases according to prognosis depending on several clinical parameters. Since there is evidence of a link between ABO blood groups and disease susceptibility, it could be argued that there is a link between blood groups and disease manifestation and progression. The current study investigates whether clinical manifestation, laboratory, and imaging findings vary among ABO blood groups of hospitalized confirmed COVID-19 patients.This retrospective cohort study was conducted between March 1, 2020 and March 31, 2021 in King Faisal Specialist Hospital and Research Centre Riyadh and Jeddah, Saudi Arabia. Demographic information, clinical information, laboratory findings, and imaging investigations were extracted from the data warehouse for all confirmed COVID-19 patients.A total of 285 admitted patients were included in the study. Of these, 81 (28.4%) were blood group A, 43 (15.1%) were blood group B, 11 (3.9%) were blood group AB, and 150 (52.6%) were blood group O. This was almost consistent with the distribution of blood groups among the Saudi Arabia community. The majority of the study participants (79.6% [n = 227]) were asymptomatic. The upper respiratory tract infection (P = .014) and shortness of breath showed statistically significant differences between the ABO blood group (P = .009). Moreover, the incidence of the symptoms was highly observed in blood group O followed by A then B except for pharyngeal exudate observed in blood group A. The one-way ANOVA test indicated that among the studied hematological parameters, glucose (P = .004), absolute lymphocyte count (P = .001), and IgA (P = .036) showed statistically significant differences between the means of the ABO blood group. The differences in both X-ray and computed tomography scan findings were statistically nonsignificant among the ABO age group. Only 86 (30.3%) patients were admitted to an intensive care unit, and the majority of them were blood groups O 28.7% (n = 43) and A 37.0% (n = 30). However, the differences in complications' outcomes were statistically nonsignificant among the ABO age group.ABO blood groups among hospitalized COVID-19 patients are not associated with clinical, hematological, radiological, and complications abnormality.

Indexed as

ABO Blood-Group SystemDisease SusceptibilityAdolescentAdultAgedAged, 80 and overCOVID-19DyspneaFemaleHumansIncidenceMaleMiddle AgedPandemicsRespiratory Tract InfectionsRetrospective StudiesABO Blood-Group System

Identifiers

PMID34967364
PMCPMC8718246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.